The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease

Chronic renal disease is significantly increased by hypertension. Controlling blood pressure is critical in hypertensive individuals. Patients who have good blood pressure (BP) control can reduce morbidity and mortality. This study aimed to compare blood pressure reduction of candesartan-amlodipine...

Full description

Bibliographic Details
Published in:	Pharmaciana
Main Authors:	Dian Ayu Juwita, Fitri Rachmaini, Almahdy, Rahmad Abdillah, Yolanda Mayestika Wati
Format:	Article
Language:	English
Published:	Universitas Ahmad Dahlan 2022-07-01
Subjects:	blood pressure candesartan amlodipine furosemide hypertension ckd
Online Access:	http://journal.uad.ac.id/index.php/PHARMACIANA/article/view/21491/pdf_238

Similar Items

Intoxication with massive doses of amlodipine and candesartan requiring venoarterial extracorporeal membrane oxygenation
by: Minagawa Yusuke, et al.
Published: (2023-01-01)

Determination of candesartan and amlodipine using ion pair and cloud point methods
by: Mohammed Mahmood Abdullah, et al.
Published: (2024-07-01)

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment
by: Moon-Seung Soh, et al.
Published: (2024-10-01)

COST-EFFECTIVENESS ANALYSIS OF AMLODIPINE AND CANDESARTAN USE IN TYPE 2 DIABETES MELLITUS PATIENTS WITH COMORBID HYPERTENSION IN YOGYAKARTA, INDONESIA
by: Ingenida Hadning, et al.
Published: (2025-08-01)

Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial
by: Takaichi Suehiro, et al.
Published: (2021-03-01)

CANDESARTAN IN CARDIOLOGY PRACTICE
by: N. A. Dzhaiani
Published: (2017-12-01)

Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
by: N. M. Chikhladze, et al.
Published: (2008-12-01)

Candesartan cilexetil in cardiovascular prevention
by: A. Ya. Ivleva
Published: (2007-12-01)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
by: Lanlan Xu, et al.
Published: (2021-09-01)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
by: Omar Y. Mady, et al.
Published: (2021-08-01)

Comparative Effects of Candesartan Versus Enalapril on Apelin, Visfatin, and Lipid Levels in Non-obese Hypertensive Patients
by: Yaseen K. JUMAAH, et al.
Published: (2024-09-01)

Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients
by: Nian Cao, et al.
Published: (2021-10-01)

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
by: Marie‐Pierre Dubé, et al.
Published: (2022-10-01)

Cerebroprotective effects of angiotensin II receptor blockers: candesartan focus
by: O. D. Ostroumova, et al.
Published: (2018-09-01)

Simultaneous Determination of Candesartan and Hydrochlorothiazide in Human Plasma by HPLC-MS/MS
by: P. K. Karnakova, et al.
Published: (2021-11-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
by: Andrés Figueroa-Campos, et al.
Published: (2020-07-01)

Candesartan Normalizes Changes in Retinal Blood Flow and p22phox in the Diabetic Rat Retina
by: Randa S. Eshaq, et al.
Published: (2021-03-01)

EFFECT OF CANDESARTAN ON PARAMETERS OFDAILYBLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEYDISEASE ON HEMODIALYSIS
by: V. A. Vizir, et al.
Published: (2017-12-01)

Candesartan: A pharmaceutical product as effective corrosion inhibitor for aluminum in acidic solution
by: Abdel Aziz Fouda, et al.
Published: (2021-09-01)

Optimization and validation of UPLC method for dapagliflozin and candesartan cilexetil in an on-demand formulation: Analytical quality by design approach
by: Elzayat Ehab M., et al.
Published: (2025-07-01)

Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM
by: Hailun Qin, et al.
Published: (2024-08-01)

Functional candesartan loaded lipid nanoparticles for the control of diabetes-associated stroke: In vitro and in vivo studies
by: Dina M. Mahmoud, et al.
Published: (2024-06-01)

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
by: Ramin Ravangard, et al.
Published: (2023-09-01)

Determination of Candesartan in Human Plasma using Liquid Chromatography - Tandem Mass Spectrometry
by: Vanja Forjan, et al.
Published: (2016-02-01)

DYNAMICS OF PARAMETERS OF PROINFLAMMATORY ACTIVATION IN PATIENTS WITH HYPERTENSION UNDER INFLUENCE OF CANDESARTAN THERAPY
by: V. A. Vizir, et al.
Published: (2014-05-01)

Novel Anti-proliferative Application of Telmisartan and Candesartan: Synergistic Repurposing Strategy Against Colorectal Cancer
by: Raneen Atiyah, et al.
Published: (2025-10-01)

Identification of Candesartan Cilexetil-L-Arginine Co-amorphous Formation and Its Solubility Test
by: Fikri Alatas, et al.
Published: (2022-02-01)

Effect of Extracellular Matrix Stiffness on Candesartan Efficacy in Anti-Fibrosis and Antioxidation
by: Tong Zhu, et al.
Published: (2023-03-01)

CHANGES IN THE PROOXIDATIVE-ANTIOXIDANT SYSTEM IN SHR SERIES RATS WITH TREATMENT OF HYPOTENSIVE MEDICINES (RAMIPRIL AND CANDESARTANE) IN COMBINATION WITH CORVITIN
by: Aliona Marushchak, et al.
Published: (2020-07-01)

Technological approaches to improve the bioavailability of the poor soluble substance Candesartan Cilexetil in mini-tablets
by: K. M. Tserkovnaya, et al.
Published: (2025-03-01)

Protective Effect of Co Q10 and Candesartan on Bleomyycin Induced Lung Fibrosis in Rats
by: Fatima Mohammad Saeed Mahdi, et al.
Published: (2022-04-01)

Secondary Effects of Hypochlorite Treatment on the Emerging Pollutant Candesartan: The Formation of Degradation Byproducts and Their Toxicological Profiles
by: Giovanni Luongo, et al.
Published: (2021-06-01)

Industrial Sustainable Decrystallizing Formulation to Enhance Dissolution of Candesartan Cilexetil: Overcoming Limitations of Traditional Solid Dispersion Approaches
by: Mohamed A. Ibrahim, et al.
Published: (2025-09-01)

Description of cardiovascular remodeling parameters and osteopontin plasma level in dynamics of the candesartan therapy in patients with chronic kidney disease on the stage before dialysis
by: V. A. Vizir, et al.
Published: (2015-04-01)

Study of Neuroprotection by a Combination of the Biological Antioxidant (<i>Eucalyptus</i> Extract) and the Antihypertensive Drug Candesartan against Chronic Cerebral Ischemia in Rats
by: Christine Trabolsi, et al.
Published: (2021-02-01)

Comparative effects of candesartan and losartan on mesangial expansion and glomerular volume in diabetes rat model receiving rosmarinic acid therapy
by: Nur Samsu, et al.
Published: (2024-03-01)

Comparative evaluation of the impact of candesartan and ramipril therapy on the levels of GDF 15 and NTproBNP, structural and functional performance of the heart in patients with coronary artery disease with asymptomatic diastolic dysfunction after myocar
by: V. D. Syvolap, et al.
Published: (2014-04-01)

Exploring Candesartan, an angiotensin II receptor antagonist, as a novel inhibitor of NLRP3 inflammasome: alleviating inflammation in Neisseria gonorrhoeae infection
by: Wen-Yu Lin, et al.
Published: (2024-11-01)

Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD
by: Margaux Costes-Albrespic, et al.
Published: (2025-07-01)